Nxstage Medical, Inc. (NXTM) Tops Q3 EPS by 2c; Lowers FY12 Outlook
Tweet
Share
E-mailGet Alerts NXTM Hot Sheet
Join SI Premium – FREE
Nxstage Medical, Inc. (NASDAQ: NXTM) reported Q3 EPS of ($0.04), $0.02 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $61.2 million versus the consensus estimate of $60.81 million.
Nxstage Medical, Inc. sees FY2012 EPS of $-0.28--0.26, versus prior guidance of $-0.32--0.25 and the consensus of $-0.29. Nxstage Medical, Inc. sees FY2012 revenue of $240-242 million, versus prior guidance of $240-245 million and the consensus of $241.40 million.
Nxstage Medical, Inc. sees FY2012 EPS of $-0.06--0.04, versus the consensus of $-0.05. Nxstage Medical, Inc. sees FY2012 revenue of $63-65 million, versus the consensus of $64.70 million.
For earnings history and earnings-related data on Nxstage Medical, Inc. (NXTM) click here.
Nxstage Medical, Inc. sees FY2012 EPS of $-0.28--0.26, versus prior guidance of $-0.32--0.25 and the consensus of $-0.29. Nxstage Medical, Inc. sees FY2012 revenue of $240-242 million, versus prior guidance of $240-245 million and the consensus of $241.40 million.
Nxstage Medical, Inc. sees FY2012 EPS of $-0.06--0.04, versus the consensus of $-0.05. Nxstage Medical, Inc. sees FY2012 revenue of $63-65 million, versus the consensus of $64.70 million.
For earnings history and earnings-related data on Nxstage Medical, Inc. (NXTM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
- Raytheon Technologies (RTX) Tops Q1 EPS by 11c; reaffirms outlook
- GATX Corp. (GATX) Tops Q1 EPS by 25c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
